<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04747795</url>
  </required_header>
  <id_info>
    <org_study_id>S63213</org_study_id>
    <secondary_id>2020-001862-12</secondary_id>
    <secondary_id>KCE 19-1237</secondary_id>
    <nct_id>NCT04747795</nct_id>
  </id_info>
  <brief_title>Early Administration of Vitamin C in Patients With Sepsis or Septic Shock in Emergency Departments</brief_title>
  <acronym>c-easie</acronym>
  <official_title>Early Administration of Vitamin C in Patients With Sepsis or Septic Shock in Emergency Departments: a Multicentre, Double Blinded, Randomized Controlled Trial: the C-EASIE Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Federaal Kenniscentrum voor Gezondheidszorg, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this clinical trial the effect of early administration of Vitamin C is investigated in&#xD;
      patients admitted at the emergency department with sepsis or septic shock.&#xD;
&#xD;
      When a patient has sepsis, his/her body is causing damage to its own tissues and organs as&#xD;
      result of an infection. This can lead to septic shock. The patient has a low blood pressure,&#xD;
      his/her organs stop working and the patient may even die.&#xD;
&#xD;
      The aim of this trial is to investigate the efficiency of Vitamin C in sepsis and septic&#xD;
      shock. Vitamin C is a vitamin present in various foods and has been approved as dietary&#xD;
      supplement by the Belgian authorities. Over the years it has been proven that Vitamin C is&#xD;
      very safe. In addition, several studies have shown that Vitamin C can also have a protective&#xD;
      effect. It can reduce organ damage and increase survival rates. Although several studies&#xD;
      suggest that Vitamin C can help fight sepsis, it is not yet used in practice. This Belgian&#xD;
      trial, in which several hospitals participate, hopes to provide a clear answer to the&#xD;
      question: &quot;Should Vitamin C be administered to patients admitted in an emergency department&#xD;
      with sepsis or septic shock?&quot;&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 5, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sequential Organ Failure Assessment (SOFA) score</measure>
    <time_frame>5 days</time_frame>
    <description>Average post-baseline patient SOFA score, SOFA score range: 0-24, with 24 being the worst outcome (death)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>28-day mortality</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum SOFA score</measure>
    <time_frame>5 days</time_frame>
    <description>Maximum SOFA score measured during 5 intervention period. SOFA score ranging from 0 to 24, with 24 begin the worst outcome (death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>3 months</time_frame>
    <description>Total length of hospital stay of the patient (including beyond intervention period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>3 months</time_frame>
    <description>Total length of ICU stay of the patient (including beyond intervention period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration Vasopressors</measure>
    <time_frame>5 days</time_frame>
    <description>Total duration where vasopression is required (hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosage Vasopressors</measure>
    <time_frame>5 days</time_frame>
    <description>Total dosage of Vasopressors required (mcg/kg/min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>need for Renal Replacement Therapy (RRT)</measure>
    <time_frame>5 days</time_frame>
    <description>was RRT needed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of Renal Replacement Therapy (RRT)</measure>
    <time_frame>5 days</time_frame>
    <description>total duration of RRT (hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator days</measure>
    <time_frame>3 months</time_frame>
    <description>Total number of days the patient requires ventilator support (including beyond intervention period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steroids</measure>
    <time_frame>5 days</time_frame>
    <description>Total dose of steroids given</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire (EQ-5D-5L)</measure>
    <time_frame>3 months</time_frame>
    <description>The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.&#xD;
The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to return to work</measure>
    <time_frame>3 months</time_frame>
    <description>Time to return to work of the patient after ED admission (in days)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Sepsis</condition>
  <condition>Septic Shock</condition>
  <condition>Sepsis, Severe</condition>
  <arm_group>
    <arm_group_label>standard care + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The 'standard care' group will receive intermittent infusion of normal saline (3 ampoules of 5 ml 9mg/ml normal saline diluted in 50 ml of normal saline, every 6 hours) during 4 days or until hospital discharge and is started within 6 hours after presentation (time of triage) in the ED.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard care + Vitamin C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The 'standard care + Vitamin C' group will receive intermittent infusion of Vitamin C (3 ampoules of 500 mg/5ml Vitamin C diluted in 50 ml of normal saline, every 6 hours) during 4 days or until hospital discharge and is started within 6 hours after presentation (time of triage) in the ED.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin C</intervention_name>
    <description>IV</description>
    <arm_group_label>standard care + Vitamin C</arm_group_label>
    <other_name>Ascorbic Acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>IV</description>
    <arm_group_label>standard care + placebo</arm_group_label>
    <other_name>physiological serum</other_name>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient has a 'suspected infection': this requires the combination of antibiotic&#xD;
             administration and body fluid cultures within the first 6 hours after Emergency&#xD;
             Department presentation.&#xD;
&#xD;
          -  Patient has a NEWS score ≥ 5.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient (≥18 years old) or legally authorized representative didn't provide informed&#xD;
             consent. Delayed informed consent can be applied in cases where the patient is&#xD;
             critically ill and no LAR is available.&#xD;
&#xD;
          -  antibiotic administration as a single dose or as a prophylactic treatment.&#xD;
&#xD;
          -  antibiotics administered without an accompanying body fluid culture according to the&#xD;
             timeframe (within 6 hours after emergency department presentation).&#xD;
&#xD;
          -  'Do no intubate' or 'comfort measures only' status.&#xD;
&#xD;
          -  Failure to randomize within 6 hours after Emergency Department presentation.&#xD;
&#xD;
          -  Weight &lt; 45 kg.&#xD;
&#xD;
          -  Pregnant or breastfeeding.&#xD;
&#xD;
          -  Known allergy for Vitamin C.&#xD;
&#xD;
          -  Known history of oxalate nephropathy or hyperoxaluria.&#xD;
&#xD;
          -  Known history of glucose-6-phosphate dehydrogenase deficiency.&#xD;
&#xD;
          -  Known history of chronic iron overload due to iron storage and other diseases.&#xD;
&#xD;
          -  The patient is already on IV steroids for a reason other than septic shock.&#xD;
&#xD;
          -  Proven active COVID-19 infection (positive swab and/or CT scan positive for COVID-19&#xD;
             within 14 days prior to or at ED presentation).&#xD;
&#xD;
          -  Participation in an interventional trial with an investigational medicinal product&#xD;
             (IMP) or device&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Didier Desruelles, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaire Ziekenhuizen Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lina Wauters, PhD</last_name>
    <phone>+3216345820</phone>
    <email>lina.wauters@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefanie Vandervelden, MD</last_name>
    <phone>+3216 345405</phone>
    <email>stefanie.vandervelden@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>GasthuisZusters Antwerpen</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Vanhove, MD</last_name>
      <phone>+3234435262</phone>
      <email>philippe.vanhove@gza.be</email>
    </contact>
    <contact_backup>
      <last_name>Brecht De Tavernier</last_name>
      <email>brecht.detavernier@gza.be</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Koen Monsieurs, MD</last_name>
      <phone>+3238214607</phone>
      <email>koen.monsieurs@uza.be</email>
    </contact>
    <contact_backup>
      <last_name>Ken Dewitte, MD</last_name>
      <email>ken.dewitte@uza.be</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Saint-Pierre Bruxelles</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magali Bartiaux, MD</last_name>
      <phone>+3225355037</phone>
      <email>magali.bartiaux@stpierre-bru.be</email>
    </contact>
    <contact_backup>
      <last_name>Katty Renard</last_name>
      <email>katty.renard@stpierre-bru.be</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Brussel</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ives Hubloue, MD</last_name>
      <phone>+322477 51 53</phone>
      <email>ives.hubloue@uzbrussel.be</email>
    </contact>
    <contact_backup>
      <last_name>Evert Verhoeven, MD</last_name>
      <email>evert.verhoeven@uzbrussel.be</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Université Libre de Bruxelles Erasme</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacques Creteur, MD</last_name>
      <phone>+322 555 44 54</phone>
      <email>jacques.creteur@erasme.ulb.ac.be</email>
    </contact>
    <contact_backup>
      <last_name>Dominique Durand</last_name>
      <email>ddurand@ulb.ac.be</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuizen Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier Desruelles, MD</last_name>
      <phone>+3216 344638</phone>
      <email>didier.desruelles@uzleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Stefanie Vandervelden, MD</last_name>
      <phone>+3216 345405</phone>
      <email>stefanie.vandervelden@uzleuven.be</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Liège</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>François Stifkens, MD</last_name>
      <phone>+3242843505</phone>
      <email>fstifkens@chuliege.be</email>
    </contact>
    <contact_backup>
      <last_name>Meryl Paquay</last_name>
      <email>Meryl.Hajaoui@uliege.be</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Algemeen Ziekenhuis Turnhout</name>
      <address>
        <city>Turnhout</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Breuls, MD</last_name>
      <phone>+3214407055</phone>
      <email>jan.breuls@azturnhout.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 4, 2021</study_first_submitted>
  <study_first_submitted_qc>February 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2021</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitamin C</keyword>
  <keyword>ascorbic acid</keyword>
  <keyword>sepsis</keyword>
  <keyword>septic shock</keyword>
  <keyword>RCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Emergencies</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

